U.S., April 29 -- ClinicalTrials.gov registry received information related to the study (NCT07553754) titled 'Plasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis' on March 11.

Brief Summary: Brief Summary:

This prospective, multicenter study aims to discover, develop, and validate a plasma exosomal RNA-based signature as a rule-out test for predicting bone metastasis in prostate cancer, using baseline treatment-naive PSMA PET as the gold standard. The study is designed in four sequential phases:

Phase 1 (Discovery, n=250): High-throughput sequencing of plasma exosomal RNAs to identify differentially expressed candidate RNAs.

Phase 2 (Model Development, n=300): Digital droplet PCR (ddPCR) analysis of candidates in an indepe...